Ionis Pharmaceuticals Inc

NASDAQ:IONS  
38.26
+0.89 (+2.38%)
4:12:49 PM EDT: $38.83 +0.57 (+1.49%)
Other Pre-Announcement

Ionis Pharmaceuticals Inc Reports Positive Topline Phase 2 Study Results Of Its Novel Antisense Treatment For Hereditary Angioedema

Published: 03/29/2021 11:34 GMT
Ionis Pharmaceuticals Inc (IONS) - Ionis Pharmaceuticals Inc - Reports Positive Topline Phase 2 Study Results of Its Novel Antisense Treatment for Hereditary Angioedema.
Ionis - Ionis-pkk-l Rx Met Its Primary and All Secondary Endpoints, Including a Mean Reduction of Up to 97% in Hae Attacks Compared to Placebo.
Ionis - Expects to Present a Full Analysis of Its Phase 2 Study of Ionis-pkk-l(rx) at a Medical Conference Later This Year.